MetaCap

AN2 Therapeutics (ANTX) vs Bright Minds Biosciences (DRUG)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

AN2 Therapeutics (ANTX) has outperformed Bright Minds Biosciences (DRUG) over the past year, gaining 366.1% versus a loss of 65.2%. Bright Minds Biosciences is the larger company by market cap ($201.2 million vs $192.8 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ANTX+366.06%DRUG-65.18%
+503%+204%-95%
Nov 21, 20251 yearNov 20, 2026
ANTX-67.01%DRUG+155.00%
+1080%+465%-150%
Mar 21, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ANTX versus DRUG key metrics
MetricANTXDRUG
Share price$5.08$20.40
Market cap$192.75M$201.23M
1-day change-2.68%-1.45%
YTD return+345.61%-73.86%
1-year return+366.06%-65.18%
5-year return—-7.27%
EPS (TTM)$-0.91$-2.05
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-35.17M—
52-week high$7.19$123.75
52-week low$1.00$17.40
Distance from 52-week high-29.35%-83.52%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+77.17%+426.18%
Average volume289.29K173.24K
Shares outstanding37.94M9.86M
Employees2126
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ANTX has outperformed DRUG by 431.2 percentage points over the past year.

About AN2 Therapeutics

ANTX stock →

AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis.

Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees

About Bright Minds Biosciences

DRUG stock →

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies.

Health Care · Biotechnology: Pharmaceutical Preparations · 26 employees

ANTX vs DRUG FAQ

Which is bigger, AN2 Therapeutics or Bright Minds Biosciences?

Bright Minds Biosciences (DRUG) is larger, with a market capitalization of $201.23M compared with $192.75M for AN2 Therapeutics (ANTX).

Which stock has performed better over the past year, ANTX or DRUG?

ANTX returned +366.06% over the past 12 months, compared with -65.18% for DRUG (price return, excluding dividends). Past performance does not predict future results.

Are AN2 Therapeutics and Bright Minds Biosciences in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons